Attendee search 

BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world. 

Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which is both physician-centric – providing superior service and support – and clinically relevant – providing innovative and disruptive technology to improve patient outcomes. What makes us different from other labs is the added value we bring through personal attention and professional support and the effort we make to understand our clients’ needs. Our success comes from helping clinicians deliver premium services to the patients in their care – through a full menu of cost–conscious testing options and cutting edge technologies with clinically–relevant results, all in a medically and fiscally responsible manner. 

In addition, BioReference has pioneered the development of business solutions for our clients, providing data and analytics to help them operate at their fullest potential. 

The Laboratory services multiple markets through several specialized business units, each with its own dedicated sales team and highly-trained support personnel. These include women’s health, oncology, genetics and a lab division focused exclusively on the nation’s expanding Spanish-speaking populations.

Clinical Diagnostics, Oncology, Women's Health, Genetic Testing

Mathew S. Maurer, MD, is medical director of The HCM Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. A general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation, he has received grants from the National Institute on Aging to study cardiovascular changes in older patients and specializes in the care of patients with heart failure and a preserved ejection fraction, including patients with HCM. Dr. Maurer is an associate professor of Medicine at Columbia University, College of Physicians and Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYork-Presbyterian Hospital. Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork-Presbyterian/Columbia.

 Led >10 biologics PKPD mathematical modeling and data analysis projects in oncology, diabetes, inflammation and Alzheimer's disease.

- Conceived the idea for a novel technology in the area of antibody drug conjugates to specifically target the tumor cells. Gathered a team of 5 to implement the technology. Got buy-in from senior management. Based on this technology, an antibody drug is being developed in Pfizer (patent in preparation).

- Co-invented a technology to improve the dosing of antibody drugs (patent application filed). A drug based on this technology is in the pipeline.

Specialties: - Feasibility analysis: Assessment of new biotherapeutic drugs, modalities and technologies
- Mechanism based translation: Preclinical to phase 1 clinical trials
- Biotherapeutics PKPD
- Monoclonal antibody drug property and dose selection
- Use of predictive mathematical modeling to design bio-better therapeutics
- Business development: Due diligence for licensing opportunities

Affordable management consulting services to startups and larger orgs in life sciences and healthcare. Team based model powered by students and recent grads in STEM, healthcare/clinical, and business backgrounds who are interested in gaining high-intensity professional development opportunities in team based environments.

Proception in-licenses Medtech IP, improves the IP, develops the products, gains regulatory approval, gains clinical experience and then out-licenses the product to a large medical device company using a unique out-licensing model.

Our mission is to help create the next generation of powerhouse biotech companies by providing entrepreneurs and innovative life-sciences startups with the space and resources they need to test out, challenge, and nurture early ideas. In order to create a fertile environment in which visionaries can thrive, we aim to:

• Foster a collaborative atmosphere that allows thought-sharing and creative exchange

• Offer best-in-class infrastructure to enable the unfettered practice of science

• Promote cost efficiencies through sharing of many services such as permitting, purchasing, maintenance, IT, and security

• Anticipate needs and roadblocks for entrepreneurs in order to provide the smoothest possible path to growth

• Create a bioinnovation ecosystem that fosters collegial interactions among industry, investors, government, and academia

Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.

U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.